Comparative Pharmacology
Head-to-head clinical analysis: BISOPROLOL FUMARATE versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISOPROLOL FUMARATE versus INDERIDE LA 120 50.
BISOPROLOL FUMARATE vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and renin release from kidneys.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Adults: Initial dose 2.5-5 mg orally once daily, titrate to 10 mg once daily; maximum 20 mg once daily.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours (mean 11 hours), allowing once-daily dosing. Half-life may be prolonged in renal impairment (creatinine clearance <40 mL/min) and in elderly patients.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Approximately 50% excreted unchanged in urine; remainder metabolized in liver to inactive metabolites, then renally excreted. Fecal excretion is negligible (<2%). Total renal clearance accounts for ~60-70% of elimination.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category C
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination